Professor Maini News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.

 E-Mail Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world. Each year, globally, chronic HBV causes an estimated 880,000 deaths from liver cirrhosis and hepatocellular carcinoma/liver cancer (HCC). The pioneering study used immune cells isolated directly from patient liver and tumour tissue, to show that targeting acyl-CoA:cholesterol acyltransferase (ACAT), an enzyme that helps to manage cholesterol levels in cells*, was highly effective at boosting immune responses. Published in Nature Communicat...